Search Results - "immunogenicity"

Shaping the "hot" immunogenic tumor microenvironment by nanoparticles co‐delivering oncolytic peptide and TGF‐β1 siRNA for boosting checkpoint blockade therapy by Cao Dai Phung, Bao Loc Nguyen, Jee‐Heon Jeong, Jae‐Hoon Chang, Sung Giu Jin, Han‐Gon Choi, Sae Kwang Ku, Jong Oh Kim

Connect to this object online.

Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - A phase III, active-controlled, randomized clinical study by Indraneel Basu, Manish Agarwal, Viral Shah, Vijay Shukla, Sunil Naik, Pravin Dinkar Supe, Manoj Kumar Srivastava, Kanakapura Vrushabaiah Giriraja, Peersab Pinjar, Pradeep Kumar Mishra, Shishir Joshi, Ranjit Vijayakumar, Serge van de Witte

Connect to this object online.

Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial by Lina Cordero De Los Santos, Jesús Feris-Iglesias, Naveena Aloysia D'Cor, Venkata Jayanth Midde, Badri Narayan Patnaik, Yaël Thollot, Anvar Rasuli, Eric Desauziers

Connect to this object online.

A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever. by Robert T Cartee, Ann Thanawastien, Thomas J Griffin Iv, John J Mekalanos, Stephan Bart, Kevin P Killeen

Connect to this object online.

A recombinant rabies virus chimera expressing the DC-targeting molecular MAB2560 shows enhanced vaccine immunogenicity through activation of dendritic cells. by Zhiyuan Gong, Pei Huang, Hongli Jin, Yujie Bai, Hailun Li, Meichen Qian, Jingxuan Sun, Cuicui Jiao, Mengyao Zhang, Yuanyuan Li, Haili Zhang, Hualei Wang

Connect to this object online.

Vaccinia Virus Protein B18R: Influence on mRNA Immunogenicity and Translation upon Non-Viral Delivery in Different Ocular Cell Types by An-Katrien Minnaert, Joke Devoldere, Karen Peynshaert, Laure Vercruysse, Stefaan C. De Smedt, Katrien Remaut

Connect to this object online.

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies by Abundio Balgos, Suad Hannawi, Wen-Li Chen, Alaa Abuquta, Linda Safeldin, Aala Hassan, Ahmad Alamadi, Louie Tirador, Anjuli May Jaen, Ralph Elvi Villalobos, Chen Mo, Zi-Jing Yue, Ying Ma, Qing-Shuang Wang, Ren-Du Wen, Zheng Yao, Jia-Ping Yu, Wen-Rong Yao, Jian-Hui Zhang, Kun-Xue Hong, Yong Liu, Jing-Xin Li

Connect to this object online.

The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months by Yu-Xiao Wang, Hong Tao, Jian-Li Hu, Jing-Xin Li, Wei-Ming Dai, Jin-Fang Sun, Pei Liu, Jie Tang, Wen-Yu Liu, Feng-Cai Zhu

Connect to this object online.

Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines by Anthony M. Marchese, Raj Kalkeri, Muruga Vadivale, Nungruthai Suntronwong, Seth Toback, Yong Poovorawan

Connect to this object online.

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults by Patrick Yassini, Mark Hutchens, Yamuna D. Paila, Lorraine Schoch, Anne Aunins, Uma Siangphoe, Robert Paris

Connect to this object online.

Clinical Protocol for a Longitudinal Cohort Study Employing Systems Biology to Identify Markers of Vaccine Immunogenicity in Newborn Infants in The Gambia and Papua New Guinea by Olubukola T. Idoko, Olubukola T. Idoko, Olubukola T. Idoko, Olubukola T. Idoko, Kinga K. Smolen, Kinga K. Smolen, Oghenebrume Wariri, Abdulazeez Imam, Casey P. Shannon, Tida Dibassey, Joann Diray-Arce, Joann Diray-Arce, Alansana Darboe, Julia Strandmark, Rym Ben-Othman, Oludare A. Odumade, Oludare A. Odumade, Oludare A. Odumade, Kerry McEnaney, Kerry McEnaney, Nelly Amenyogbe, William S. Pomat, Simon van Haren, Simon van Haren, Guzmán Sanchez-Schmitz, Guzmán Sanchez-Schmitz, Ryan R. Brinkman, Ryan R. Brinkman, Hanno Steen, Hanno Steen, Hanno Steen, Robert E. W. Hancock, Scott J. Tebbutt, Scott J. Tebbutt, Scott J. Tebbutt, Peter C. Richmond, Peter C. Richmond, Anita H. J. van den Biggelaar, Tobias R. Kollmann, Ofer Levy, Ofer Levy, Ofer Levy, Al Ozonoff, Al Ozonoff, Beate Kampmann, Beate Kampmann

Connect to this object online.

Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant by Gabiria Pastore, Jacopo Polvere, Fabio Fiorino, Simone Lucchesi, Giorgio Montesi, Ilaria Rancan, Sara Zirpoli, Arianna Lippi, Miriam Durante, Massimiliano Fabbiani, Mario Tumbarello, Francesca Montagnani, Donata Medaglini, Annalisa Ciabattini

Connect to this object online.

A recombinant rabies virus chimera expressing the DC-targeting molecular MAB2560 shows enhanced vaccine immunogenicity through activation of dendritic cells by Zhiyuan Gong, Pei Huang, Hongli Jin, Yujie Bai, Hailun Li, Meichen Qian, Jingxuan Sun, Cuicui Jiao, Mengyao Zhang, Yuanyuan Li, Haili Zhang, Hualei Wang

Connect to this object online.

Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: a non-inferiority, randomised controlled trial by Yan Li, Fan Gao, Yamin Wang, Jing Li, Yuxi Zhang, Huakun Lv, Shenyu Wang, Haitao Yang, Xiaoqiang Liu, Keli Li, Huaqing Wang, Zundong Yin, Zhenglun Liang, Zhijie An, Qunying Mao, Zijian Feng

Connect to this object online.

Correction: Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms. by Nessrin Alomran, Jaffer Alsolaiss, Laura-Oana Albulescu, Edouard Crittenden, Robert A Harrison, Stuart Ainsworth, Nicholas R Casewell

Connect to this object online.

A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly by Lili Huang, Ling Wang, Hong Li, Yuansheng Hu, Weiping Ru, Weixiao Han, Gang Shi, Qiang Ye, Zhen Han, Jielai Xia, Shengli Xia, Miao Xu, Jing Li

Connect to this object online.

Immunogenicity and safety of BNT162b2 mRNA COVID-19 vaccine in a subject affected by Shapiro's syndrome: A case report by Lorenza Moscara, Silvio Tafuri, Delio Gagliardi, Pasquale Stefanizzi

Connect to this object online.

Correction: Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms by Nessrin Alomran, Jaffer Alsolaiss, Laura-Oana Albulescu, Edouard Crittenden, Robert A. Harrison, Stuart Ainsworth, Nicholas R. Casewell

Connect to this object online.

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial by Chris Wynne, Christian Schwabe, Emmanuelle Vincent, Armin Schueler, Janka Ryding, Martin Ullmann, Vishal Ghori, Radmila Kanceva, Michael Stahl

Connect to this object online.

Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever. by Delphine Pannetier, Stéphanie Reynard, Marion Russier, Xavier Carnec, Sylvain Baize

Connect to this object online.